CEREDA, VITTORE
CEREDA, VITTORE
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
2013-10-01 Roselli, M; Cereda, V; di Bari, M; Formica, V; Spila, A; Jochems, C; Farsaci, B; Donahue, R; Gulley, J; Schlom, J; Guadagni, F
Immune reaction and colorectal cancer: friends or foes?
2014-09-21 Formica, V; Cereda, V; Nardecchia, A; Tesauro, M; Roselli, M
Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer
2013-06-01 Vergati, M; DELLA MORTE, D; Ferroni, P; Cereda, V; Tosetto, L; La Farina, F; Guadagni, F; Roselli, M
Issues and promises of bevacizumab in prostate cancer treatment
2018-01-01 Cereda, V; Formica, V; Roselli, M
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges
2015-01-01 Cereda, V; Formica, V; Menghi, A; Pellicori, S; Roselli, M
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)
2013-12-01 Formica, V; Cereda, V; di Bari, M; Grenga, I; Tesauro, M; Raffaele, P; Ferroni, P; Guadagni, F; Roselli, M
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients
2014-09-01 Formica, V; Luccchetti, J; Cunningham, D; Smyth, E; Ferroni, P; Nardecchia, A; Tesauro, M; Cereda, V; Guadagni, F; Roselli, M
Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches
2014-04-01 Cereda, V; Formica, V; Massimiani, G; Tosetto, L; Roselli, M
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy
2016-01-01 Roselli, M; Formica, V; Cereda, V; Jochems, C; Richards, J; Grenga, I; Orlandi, A; Ferroni, P; Guadagni, F; Schlom, J
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio
2014-07-15 Ferroni, P; Riondino, S; Formica, V; Cereda, V; Tosetto, L; La Farina, F; Valente, M; Vergati, M; Guadagni, F; Roselli, M
| Data di pubblicazione | Titolo | Autore(i) | Tipo | File |
|---|---|---|---|---|
| 1-ott-2013 | Effects of conventional therapeutic interventions on the number and function of regulatory T cells | Roselli, M; Cereda, V; di Bari, M; Formica, V; Spila, A; Jochems, C; Farsaci, B; Donahue, R; Gulley, J; Schlom, J; Guadagni, F | Articolo su rivista | |
| 21-set-2014 | Immune reaction and colorectal cancer: friends or foes? | Formica, V; Cereda, V; Nardecchia, A; Tesauro, M; Roselli, M | Articolo su rivista | |
| 1-giu-2013 | Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer | Vergati, M; DELLA MORTE, D; Ferroni, P; Cereda, V; Tosetto, L; La Farina, F; Guadagni, F; Roselli, M | Articolo su rivista | |
| 1-gen-2018 | Issues and promises of bevacizumab in prostate cancer treatment | Cereda, V; Formica, V; Roselli, M | Articolo su rivista | |
| 1-gen-2015 | Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges | Cereda, V; Formica, V; Menghi, A; Pellicori, S; Roselli, M | Articolo su rivista | |
| 1-dic-2013 | Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B) | Formica, V; Cereda, V; di Bari, M; Grenga, I; Tesauro, M; Raffaele, P; Ferroni, P; Guadagni, F; Roselli, M | Articolo su rivista | |
| 1-set-2014 | Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients | Formica, V; Luccchetti, J; Cunningham, D; Smyth, E; Ferroni, P; Nardecchia, A; Tesauro, M; Cereda, V; Guadagni, F; Roselli, M | Articolo su rivista | |
| 1-apr-2014 | Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches | Cereda, V; Formica, V; Massimiani, G; Tosetto, L; Roselli, M | Articolo su rivista | |
| 1-gen-2016 | The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy | Roselli, M; Formica, V; Cereda, V; Jochems, C; Richards, J; Grenga, I; Orlandi, A; Ferroni, P; Guadagni, F; Schlom, J | Articolo su rivista | |
| 15-lug-2014 | Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio | Ferroni, P; Riondino, S; Formica, V; Cereda, V; Tosetto, L; La Farina, F; Valente, M; Vergati, M; Guadagni, F; Roselli, M | Articolo su rivista |